Bausch + Lomb (BLCO) Expected to Release Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is expected to issue its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of $0.2145 per share and revenue of $1.37 billion for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.01). The business had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.37 billion. Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. Bausch + Lomb’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) earnings per share. On average, analysts expect Bausch + Lomb to post $0.81 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Bausch + Lomb Price Performance

Shares of BLCO opened at $16.91 on Wednesday. The business’s 50-day moving average is $17.15 and its two-hundred day moving average is $16.47. The company has a market capitalization of $6.04 billion, a P/E ratio of -35.23, a P/E/G ratio of 0.52 and a beta of 0.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.02 and a current ratio of 1.55. Bausch + Lomb has a fifty-two week low of $14.44 and a fifty-two week high of $18.92.

Insider Transactions at Bausch + Lomb

In related news, Director Eschenbach Andrew C. Von sold 6,059 shares of Bausch + Lomb stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $16.58, for a total value of $100,458.22. Following the completion of the transaction, the director owned 63,733 shares in the company, valued at $1,056,693.14. The trade was a 8.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Frederick Munsch sold 52,900 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $16.78, for a total value of $887,662.00. Following the completion of the transaction, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at $769,044.18. The trade was a 53.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 71,459 shares of company stock worth $1,194,370 over the last 90 days. Insiders own 1.45% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Bausch + Lomb in a report on Friday, August 28th. Leerink Partners started coverage on Bausch + Lomb in a report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 target price on the stock. Evercore set a $17.00 price target on Bausch + Lomb in a research report on Monday, July 6th. Citigroup lifted their price target on Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Barclays raised Bausch + Lomb to a “strong-buy” rating in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $19.46.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.